Verona, Italy

Adolfo Prandi

This inventor holds 1 USPTO granted patent. Top assignee: Glaxo Group Limited. Active years: 2010.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Adolfo Prandi. Retrieved from https://idiyas.com/inventor/adolfo-prandi-6x8fi5h4

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2010

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Adolfo Prandi: Innovator in Dopamine Modulation

Introduction

Adolfo Prandi is a notable inventor based in Verona, Italy. He has made significant contributions to the field of pharmacology, particularly in the modulation of dopamine receptors. His work has implications for various therapeutic applications, showcasing the importance of innovation in medical science.

Latest Patents

Adolfo Prandi holds a patent for "Azabicyclo [3.1.0] hexylphenyl derivatives as modulators of dopamine D3 receptors." This invention relates to novel compounds that can influence dopamine receptor activity, which is crucial for developing treatments for various neurological conditions. He has 1 patent to his name, reflecting his focused contributions to this specialized area of research.

Career Highlights

Prandi is associated with Glaxo Group Limited, a prominent player in the pharmaceutical industry. His role in this company has allowed him to work on groundbreaking research that bridges the gap between chemistry and medicine. His expertise in the field has positioned him as a valuable asset in the development of new therapeutic agents.

Collaborations

Throughout his career, Adolfo has collaborated with esteemed colleagues such as Gabriella Gentile and Dieter Hamprecht. These partnerships have fostered an environment of innovation and creativity, leading to advancements in their shared research interests.

Conclusion

Adolfo Prandi's work exemplifies the critical role of inventors in advancing medical science. His patent on dopamine D3 receptor modulators highlights the potential for new treatments in neurology. Through his career at Glaxo Group Limited and collaborations with other experts, he continues to contribute to the field of pharmacology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…